Any current/future new fundraising through debt or equity?

There is no direct mention of any ongoing or planned new fundraising through debt or equity in the transcript. The company is focusing on expanding bed capacity and operational utilization internally before considering new assets. Growth strategies are centered on leveraging existing infrastructure and partnerships rather than immediate capital raising. The management emphasizes improving operating efficiencies and profitability using current resources. No explicit comments were made regarding raising fresh equity or debt funding for expansion or other needs at this time.

Any current/future capex/capital investment/strategic investment?

Installation and operationalization of cath labs at KLS Memorial Hospital and Prannath Hospital, enhancing cardiology and cardiac surgery capabilities. Expansion plans at Prannath Hospital include: - Launching cardiac surgery department soon. - Applying for renal transplant program approval. - Planning radiotherapy and comprehensive cancer care unit (awaiting corporation approvals). Development of a state-of-the-art Valsad hospital with 120 beds expected to be operational by Q1 FY25. Expansion in Tulip Agility Private Limited with focus on elderly care and allied health conce

Future growth expectations in sales/revenue/volumes?

FY25 revenue target is INR 45-50 crores; FY26 target is around INR 60 crores. Valsad unit expected to add revenue of INR 1.25 crores initially, potentially growing up to INR 2.5-3 crores/month post-launch (expected Q1 FY25). Prannath Hospital revenue currently INR 40-45 lakhs/month, potentially reaching INR 2 crores/month within 2 years. Current bed utilization at ~55% (250 beds used out of 555); strategy focuses on increasing utilization to 100% by 2025 to drive organic growth without adding beds immediately. OPD utilization is at 50%; plans to increase OPD volumes across units — e.g.

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue targets are set at INR 45-50 crores for FY25 and INR 60 crores for FY26, with potential upside of INR 10 crores if Valsad unit becomes operational by March 2025. The newly acquired and partnership units are already at or near cash breakeven, supporting bottom-line growth without additional financial obligations. Major revenue drivers include Prannath Hospital (expected INR 40-45 lakhs per month initially, scaling to INR 2 crores/month over 2 years) and Valsad (potential INR 1.25-3 crores/month). Operated beds utilization is currently ~50%, with a goal to increase to 100% by 2025,

Maitreya Medica.Q2 FY25Healthcare Services

Maitreya Medica. Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹125Market Cap: ₹85 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

FY25 revenue target is INR 45-50 crores; FY26 target is around INR 60 crores.
Valsad unit expected to add revenue of INR 1.25 crores initially, potentially growing up to INR 2.5-3 crores/month post-launch (expected Q1 FY25).
Prannath Hospital revenue currently INR 40-45 lakhs/month, potentially reaching INR 2 crores/month within 2 years.
Current bed utilization at ~55% (250 beds used out of 555); strategy focuses on increasing utilization to 100% by 2025 to drive organic growth without adding beds immediately.
OPD utilization is at 50%; plans to increase OPD volumes across units — e.g., Surat handling 100 OPDs/day, Prannath 250/day, Valsad expected 200/day at full operation.
Emphasis on enhancing internal efficiency, technology upgrades, and expanding specialties to boost revenue and profitability.
Management contracts contribute to bottom line without additional cost, providing incremental revenue streams.

Margin guidance

Category 3

Revenue targets are set at INR 45-50 crores for FY25 and INR 60 crores for FY26, with potential upside of INR 10 crores if Valsad unit becomes operational by March 2025.
The newly acquired and partnership units are already at or near cash breakeven, supporting bottom-line growth without additional financial obligations.
Major revenue drivers include Prannath Hospital (expected INR 40-45 lakhs per month initially, scaling to INR 2 crores/month over 2 years) and Valsad (potential INR 1.25-3 crores/month).
Operated beds utilization is currently ~50%, with a goal to increase to 100% by 2025, which will boost top and bottom line.
Expansion plans focus on both asset ownership and operations/management models to balance growth and financial health.
Profit margins may moderate short term due to investments in professional skills but expected to improve with operational maturity.
Overall, FY25-FY26 anticipated to be game-changing years with increased earnings and EPS growth.

See what Maitreya Medica. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no direct mention of any ongoing or planned new fundraising through debt or equity in the transcript.
The company is focusing on expanding bed capacity and operational utilization internally before considering new assets.
Growth strategies are centered on leveraging existing infrastructure and partnerships rather than immediate capital raising.
The management emphasizes improving operating efficiencies and profitability using current resources.
No explicit comments were made regarding raising fresh equity or debt funding for expansion or other needs at this time.

Order book

- There is no explicit mention of a current or expected order book or pending orders in the transcript. - The focus is primarily on the operational and management status of hospital units, beds, revenues, and expansions. - New acquisitions and partnerships are on cash breakeven with no financial obligations, aiming for growth via increased utilization. - Expansion plans include opening and operationalizing new units such as Valsad hospital (expected operational by Q1 FY25) and increasing bed utilization from 55% to 100%. - Potential future acquisitions or bed additions will be considered when the right opportunities arise. - The company is focusing on optimal usage and internal efficiencies before pursuing aggressive new asset acquisitions. In summary, the transcript does not detail order books or pending orders but emphasizes operational growth, bed utilization, and selective future acquisitions.

See what Maitreya Medica. management said on order book — free account, 30 seconds.

Capex plans

Yes

Installation and operationalization of cath labs at KLS Memorial Hospital and Prannath Hospital, enhancing cardiology and cardiac surgery capabilities.
Expansion plans at Prannath Hospital include:
- Launching cardiac surgery department soon.
- Applying for renal transplant program approval.
- Planning radiotherapy and comprehensive cancer care unit (awaiting corporation approvals).
Development of a state-of-the-art Valsad hospital with 120 beds expected to be operational by Q1 FY25.
Expansion in Tulip Agility Private Limited with focus on elderly care and allied health concepts, planning for multi-city growth.
Leveraging existing infrastructure through partnerships with hospitals like KLS Memorial, Smit Hospital (Nandurbar), and Prannath for clinical and operational management agreements to optimize assets and growth.
Emphasis on increasing bed utilization from current 55% to 100% operational beds by 2025 for enhanced revenue.

Track Maitreya Medica. — get its next earnings analysis in your feed

How does Maitreya Medica. rank vs peers in Healthcare Services?

Pro feature

ThisMaitreya Medica.

Rev 3Mar 3

See where Maitreya Medica. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Maitreya Medica. rank in Healthcare Services?

Compare Maitreya Medica. against every Healthcare Services company (Q2 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Maitreya Medica.'s management said in earlier quarters

Others in Healthcare Services this season

Rainbow Childrens Medicare Ltd (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Maitreya Medica. Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Maitreya Medica. rank in Healthcare Services?

Continue your research

What Maitreya Medica.'s management said in earlier quarters

Others in Healthcare Services this season